Thus, the use of genetic or pharmaceutical approaches to inhibit the Hippo/YAP/14-3-3η pathway to improve mitochondrial function and ameliorate synaptic impairment in the BLA neuron may provide another avenue for therapeutic development in MDD. The gene discussed is YAP1; the disease is major depressive disorder.